Foghorn Therapeutics Files 8-K
Ticker: FHTX · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Foghorn Therapeutics filed an 8-K, no major news yet.
AI Summary
Foghorn Therapeutics Inc. filed an 8-K on March 20, 2025, reporting other events and financial statements. The filing does not contain specific details on new agreements, material events, or financial figures beyond the reporting date.
Why It Matters
This 8-K filing indicates that Foghorn Therapeutics Inc. has made a regulatory submission, but it does not disclose any specific material events or financial updates that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K and does not contain any new material information, agreements, or financial disclosures that would indicate increased risk.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — Registrant
- March 20, 2025 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is a Current Report filed by Foghorn Therapeutics Inc. to report 'Other Events' and 'Financial Statements and Exhibits' as of March 20, 2025.
What specific material events are disclosed in this filing?
The provided text of the 8-K filing does not specify any particular material events; it only lists the categories of information being reported.
When was this filing submitted?
The filing was submitted on March 20, 2025.
What is Foghorn Therapeutics Inc.'s principal executive office address?
Foghorn Therapeutics Inc.'s principal executive offices are located at 500 Technology Square, Ste 700, Cambridge, MA 02139.
What is Foghorn Therapeutics Inc.'s state of incorporation?
Foghorn Therapeutics Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding Foghorn Therapeutics Inc. (FHTX).